VTRS

Viatris Inc.

Healthcare
15.56 -0.13 -0.83% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 18.12B
EV —
Shares Out 1.16B
Revenue (ttm) 14.52B
Net Income -296.50M
Beta —
P/E -60.63
Forward P/E —
EPS (ttm) $-0.30
P/S 1.24
P/B 1.23
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA -0.8%
ROE -1.96%
ROIC 0.16%
Gross Margin 34.51%
Oper. Margin 0.96%
Profit Margin -2.04%
Debt/Eq 1.13
LT Debt/Eq 45.86%
Quick Ratio —
Current Ratio 1.60
Book/sh 12.69
Cash/sh 1.56
Div Yield 3.08%
Div TTM $0.48
Payout Ratio —
SMA20 -5.71%
SMA50 3.3%
SMA200 22.87%
Volume 6,971,626
Avg Volume 11.00M
Rel Volume —
Perf Week -4.30%
Perf Month 0.26%
Perf Quarter 7.09%
Perf Half Y 42.36%
Perf YTD 24.98%
Perf Year 83.92%
Perf 3Y 66.77%
Perf 5Y 1.10%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.1200
TTM Yield 3.08%
TTM Amount $0.48
Payout Ratio —
3-Yr Growth (CAGR) 0.00%
5-Yr Growth (CAGR) —

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.1200
Q1 2025 ~2025-12-31 $0.1200
Q3 2025 ~2025-09-30 $0.1200
Q2 2025 ~2025-06-30 $0.1200
Q1 2025 ~2025-03-31 $0.1200
Q4 2024 ~2024-12-30 $0.1200
Q3 2024 ~2024-09-30 $0.1200
Q2 2024 ~2024-06-30 $0.1200
Q1 2024 ~2024-03-31 $0.1200
Q3 2023 ~2023-09-30 $0.1200
Q3 2023 ~2023-08-04 $0.1200
Q2 2023 ~2023-06-30 $0.1200

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Viatris Inc. is a global pharmaceutical company formed through the combination of Mylan N.V. with Pfizer's Upjohn business in November 2020. The company develops, manufactures, and distributes a diverse portfolio of branded medicines and generic drugs across four reportable segments: Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China. In 2025, Viatris sold more than 70 billion doses of medicine across more than 165 countries and territories. The company's approach bridges the traditional divide between generics and brands, combining the strengths of both to address healthcare needs globally. The company's business includes established brands such as Lipitor, Norvasc, Lyrica, EpiPen, Viagra, Creon, and Celebrex, as well as a significant generics portfolio. Viatris also maintains an innovative pipeline with late-stage and in-market growth assets sourced both internally and externally. The company operates manufacturing and distribution facilities worldwide and serves retail and pharmacy establishments, wholesalers, governments, institutions, and physicians. In 2025, Viatris delivered total revenues of $14.3 billion, returned over $1 billion to shareholders through dividends and share repurchases, and completed 60 regional transactions including the acquisition of Aculys Pharma in Japan.

Name
Viatris Inc.
Industry
Drug Manufacturers - General
CEO
Scott A. Smith · Chief Executive Officer
Employees
40,300 as of 2025-12-31
IPO Date
2019-10-25
Phone
(724) 514-1465
Address
1000 Mylan Blvd., Canonsburg, PA 15317
Website
http://www.viatris.com

Key Executives

Name Title FY Pay
Leo Groothuis General Counsel (HAL Holding N.V., 2022-present) —
Elisha Finney Executive Vice President and Chief Financial Officer (1999-2017, Varian Medical Systems) —
JoEllen Lyons Dillon Executive Vice President, Strategic Developments and Capital Markets (2014-2017) —
Frank D'Amelio Executive Vice President and Chief Financial Officer (Pfizer, 2020-2022) —
Scott A. Smith Chief Executive Officer —

Latest News